ELVN Insider Sale: President/CEO Disposes 3,700 Shares, Retains 915,392 via Trust

Q: What did Enliven Therapeutics (ELVN) insider Samuel Kintz sell?

He sold 3,700 shares of Enliven Therapeutics common stock on 09/26/2025 .

Q: Were the sales by the insider part of a trading plan?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 .

Q: How many ELVN shares does Samuel Kintz beneficially own after the transaction?

He beneficially owns 915,392 shares indirectly through The Kintz & Egan Trust dated March 30, 2019.

Q: What is the reporting person's role at Enliven Therapeutics?

The reporting person, Samuel Kintz, is listed as President and CEO and a Director of Enliven Therapeutics.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Samuel Kintz, President, CEO and a director of Enliven Therapeutics, Inc. (ELVN), reported a sale of 3,700 shares of the company's common stock on 09/26/2025. The sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024, and executed in multiple trades at prices ranging from $20.00 to $20.27, with a weighted average price of $20.0615. After the reported disposition, the reporting person beneficially owns 915,392 shares indirectly through The Kintz & Egan Trust dated March 30, 2019, for which he serves as trustee. The Form 4 is signed by a power of attorney on behalf of the reporting person.

Positive

Sale executed under a Rule 10b5-1 trading plan, indicating pre-planned transactions and reduced information asymmetry
Substantial beneficial ownership retained: 915,392 shares held indirectly via a trust, showing continued alignment with shareholders

Negative

Insider disposition of 3,700 shares was reported, which is a reduction in beneficial ownership (though small relative to total holdings)

Insights

TL;DR: A small insider sale under a pre-established 10b5-1 plan; substantial indirect ownership remains.

The Form 4 discloses a routine disposition of 3,700 shares by the company's President and CEO, executed under a previously adopted Rule 10b5-1 plan. The sale price range ($20.00–$20.27) and weighted average ($20.0615) are reported, and the filer retains significant indirect holdings (915,392 shares) via a trust. Because the sale was planned under a 10b5-1 arrangement and represents a small fraction of total beneficial ownership, this filing is informational and not clearly material to the company’s valuation.

TL;DR: Disclosure aligns with governance best practices; 10b5-1 usage reduces likelihood of informational asymmetry.

The reporting indicates adherence to a Rule 10b5-1 trading plan adopted on November 15, 2024, which provides pre-clearance and reduces concerns about opportunistic insider trading. The continued large indirect position (held in a trust for which the reporting person is trustee) suggests ongoing alignment with shareholders. The filing includes standard footnotes explaining execution and record ownership, and it is signed by an attorney-in-fact, consistent with routine practice.

Insider Trade Summary

Net Seller: 3,700 shares ($74,228)

Net Sell 1 txn

Insider Kintz Samuel

Role PRESIDENT AND CEO

Sold 3,700 shs ($74K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,700	$20.0615	$74K

Holdings After Transaction: Common Stock — 915,392 shares (Indirect, See footnote)

Footnotes (1)

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. This transaction was executed in multiple trades at prices ranging from $20.00 to $20.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.

Form 4 Insider Transactions: What Each Field Means →

09/30/2025 - 05:51 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Kintz Samuel

(Last)

(First)

(Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER

80301

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/26/2025		S⁽¹⁾		3,700	D	$20.0615⁽²⁾	915,392	I	See footnote⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

2. This transaction was executed in multiple trades at prices ranging from $20.00 to $20.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.

	/s/ Ben Hohl, by power of attorney	09/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Enliven Therapeutics (ELVN) insider Samuel Kintz sell?

He sold 3,700 shares of Enliven Therapeutics common stock on 09/26/2025.

At what price were the ELVN shares sold by the reporting person?

The shares were sold in multiple trades at prices ranging from $20.00 to $20.27, with a weighted average of $20.0615.

Were the sales by the insider part of a trading plan?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024.

How many ELVN shares does Samuel Kintz beneficially own after the transaction?

He beneficially owns 915,392 shares indirectly through The Kintz & Egan Trust dated March 30, 2019.

What is the reporting person's role at Enliven Therapeutics?

The reporting person, Samuel Kintz, is listed as President and CEO and a Director of Enliven Therapeutics.